

**SCHEMA**

**Screen prior to first chemotherapy:** Approximately **1600** breast cancer patients scheduled to receive a chemotherapy regimen that contains doxorubicin, and/or cyclophosphamide, and/or carboplatin provided on a single day and an antiemetic regimen using the antiemetics recommended in the ASCO Clinical Practice Guidelines.

**Prior to first chemotherapy:** Informed consent, Eligibility Checklist, Participant Information, FACT-G, Medical Symptom Checklist, On-Study Form, Current Prescription Medications, blood draw for biomarker/genetic assessments


**First Chemotherapy Cycle**

**Post-treatment assessments:** Four-day Home Record (nausea and vomiting), MASCC Antiemesis Tool (MAT), FACT-G, Medical Symptom Checklist,

**If nausea  $\geq 3$  (on a 1-7 scale)**

**If nausea  $< 3$ , participant is off study**

**RANDOMIZED PORTION OF CLINICAL TRIAL**  
**Stratify by NCORP site, vomiting (yes, no), setting (neo-adjuvant, adjuvant or metastatic) and whether participant is receiving a doxorubicin-based chemotherapy**



**Post-treatment assessments:** 4-Day Home Record, MAT, FACT-G, Medical Symptom Checklist

Note: Placebo<sup>1</sup> matches olanzapine and placebo<sup>2</sup> matches prochlorperazine.